- Home
- KLXE vs ANL Comparison
KLXE vs ANL Comparison
Compare KLXE & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLXE
- ANL
- Stock Information
- Founded
- KLXE 2018
- ANL 2004
- Country
- KLXE United States
- ANL Cayman Islands
- Employees
- KLXE N/A
- ANL N/A
- Industry
- KLXE Oilfield Services/Equipment
- ANL
- Sector
- KLXE Energy
- ANL
- Exchange
- KLXE Nasdaq
- ANL Nasdaq
- Market Cap
- KLXE 83.1M
- ANL 81.9M
- IPO Year
- KLXE N/A
- ANL 2023
- Fundamental
- Price
- KLXE $3.31
- ANL $2.14
- Analyst Decision
- KLXE Hold
- ANL Strong Buy
- Analyst Count
- KLXE 1
- ANL 2
- Target Price
- KLXE $4.50
- ANL $9.00
- AVG Volume (30 Days)
- KLXE 209.2K
- ANL 5.9K
- Earning Date
- KLXE 03-12-2025
- ANL 04-08-2025
- Dividend Yield
- KLXE N/A
- ANL N/A
- EPS Growth
- KLXE N/A
- ANL N/A
- EPS
- KLXE N/A
- ANL N/A
- Revenue
- KLXE $709,300,000.00
- ANL $5,000,000.00
- Revenue This Year
- KLXE $7.39
- ANL N/A
- Revenue Next Year
- KLXE $4.87
- ANL N/A
- P/E Ratio
- KLXE N/A
- ANL N/A
- Revenue Growth
- KLXE N/A
- ANL N/A
- 52 Week Low
- KLXE $3.19
- ANL $1.85
- 52 Week High
- KLXE $8.13
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- KLXE 36.98
- ANL 47.06
- Support Level
- KLXE $3.41
- ANL $1.85
- Resistance Level
- KLXE $3.65
- ANL $2.49
- Average True Range (ATR)
- KLXE 0.35
- ANL 0.15
- MACD
- KLXE -0.03
- ANL -0.03
- Stochastic Oscillator
- KLXE 7.30
- ANL 45.31
About KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.